Normally, when the contract is being made, the company and the hospital research team will preidentify milestone information and preidentify information release strategy. It is unusual in an open label phI for any company to sign on to closed results and to be frank I doubt Leo did. Actually, we know he didn't because he did give lack of toxicity in cohort one update. Again - the most likely scenario is that he is trying to adhere to more mature phase behavior to look good in eyes of fda when he goes for most rapid approval...